Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Clinical trial NCT04063462 · UNKNOWN

Trial details

NCT number: NCT04063462
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2019-10-01
Primary completion: 2021-04-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.